NCT02447003 2020-12-16Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)Merck Sharp & Dohme LLCPhase 2 Completed254 enrolled 22 charts